At the heart of the case is the language of the 340B program statute itself.

Arnold & Porter Kaye Scholer attorney Allon Kedem argued during a Monday hearing that the wording allows AstraZeneca to limit when it offers discounted prices. But U.S. Department of Justice attorney Kate Talmor said the company’s focus on how the law’s wording should be interpreted is a strategy for AstraZeneca to divert attention from its Congressionally intended general purpose of providing drug discounts to covered entities.